Progastrin: An Overview of Its Crucial Role in the Tumorigenesis of Gastrointestinal Cancers

Area of Science:

• Oncology
• Gastroenterology
• Immunology

Background:

• Defining predictive biomarkers for targeted therapies and optimizing anti-tumor immune response remains a significant challenge.
• Progastrin, a precursor to gastrin, is implicated in cell proliferation and tumorigenesis within the gastrointestinal tract.
• In cancer, progastrin accumulates as a detectable circulating protein (hPG80) instead of maturing into gastrin.

Purpose of the Study:

• To review the intricate relationship between gastrointestinal cancers and progastrin.
• To explore the molecular mechanisms underlying cancer initiation, evolution, and progression involving progastrin.
• To investigate the clinical utility of progastrin as a diagnostic and prognostic biomarker and a potential therapeutic target.

Main Methods:

• Literature review focusing on progastrin's role in gastrointestinal malignancies.
• Analysis of molecular pathways involved in cancer development and progastrin's involvement.
• Evaluation of current and potential clinical applications of progastrin in cancer management.

Main Results:

• Progastrin secretion is associated with increased cell proliferation, potentially promoting gastrointestinal tumorigenesis.
• Cancer cells fail to fully process progastrin into gastrin, leading to its accumulation as hPG80.
• Understanding progastrin-immune system interactions is crucial for future cancer strategies.

Conclusions:

• Progastrin is a key player in gastrointestinal cancer development and progression.
• hPG80 shows promise as a circulating tumor biomarker for diagnosis, prognosis, and monitoring treatment effectiveness.
• Progastrin represents a potential innovative target for novel cancer therapies.